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Abstract
Proinsulin has been characterized as a neuroprotective molecule. In this work we assess the therapeutic potential
of proinsulin on photoreceptor degeneration, synaptic connectivity, and functional activity of the retina in the
transgenic P23H rat, an animal model of autosomal dominant retinitis pigmentosa (RP). P23H homozygous rats
received an intramuscular injection of an adeno-associated viral vector serotype 1 (AAV1) expressing human
proinsulin (hPi + ) or AAV1-null vector (hPi - ) at P20. Levels of hPi in serum were determined by enzyme-linked
immunosorbent assay (ELISA), and visual function was evaluated by electroretinographic (ERG) recording at
P30, P60, P90, and P120. Preservation of retinal structure was assessed by immunohistochemistry at P120.
Human proinsulin was detected in serum from rats injected with hPi + at all times tested, with average hPi levels
ranging from 1.1 nM (P30) to 1.4 nM (P120). ERG recordings showed an amelioration of vision loss in hPi +
animals. The scotopic b-waves were significantly higher in hPi + animals than in control rats at P90 and P120.
This attenuation of visual deterioration correlated with a delay in photoreceptor degeneration and the preser-
vation of retinal cytoarchitecture. hPi + animals had 48.7% more photoreceptors than control animals. Pre-
synaptic and postsynaptic elements, as well as the synaptic contacts between photoreceptors and bipolar or
horizontal cells, were preserved in hPi + P23H rats. Furthermore, in hPi + rat retinas the number of rod bipolar
cell bodies was greater than in control rats. Our data demonstrate that hPi expression preserves cone and rod
structure and function, together with their contacts with postsynaptic neurons, in the P23H rat. These data
strongly support the further development of proinsulin-based therapy to counteract retinitis pigmentosa.
Introduction
Retinitis pigmentosa (RP) constitutes a large hetero-geneous group of inherited neurodegenerative retinal
disorders that cause a progressive loss of retinal function and
represent a major cause of blindness. More than 100 different
mutations in the rhodopsin-encoding gene (RHO) are associ-
ated with RP, together accounting for 30% to 40% of autoso-
mal dominant cases. The P23H mutation in RHO is the most
prevalent cause of RP (Dryja et al., 1990), which alone accounts
for approximately 12% of autosomal dominant RP cases in the
United States (Dryja et al., 2000). The majority of RP-causing
mutations in theRHO gene, including P23H, causemisfolding
and retention of rhodopsin in the endoplasmic reticulum of
transfected cultured cells (Kaushal and Khorana, 1994). These
studies also suggest that the mechanism of RP involves a
cellular stress response (Illing et al., 2002), the final common
pathway being programmed photoreceptor cell death by
apoptosis (Reme et al., 1998). P23H transgenic albino rats
suffer from a progressive retinal degeneration, which is con-
sistent with the clinical findings in P23Hpatients (Berson et al.,
1991; Cuenca et al., 2004; Machida et al., 2000; Pinilla et al.,
2005). The loss of photoreceptors is accompanied by degen-
erative changes in the inner retina (Cuenca et al., 2004;
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Marc et al., 2003; Puthussery and Taylor, 2010), and a sub-
stantial degeneration of retinal ganglion cells ( Jones et al.,
2003; Kolomiets et al., 2010).
Several strategies are being investigated to slow or cure this
group of diseases. Gene therapy, encapsulated cells releasing
neurotrophic factors, and stem cell transplantation are hope-
ful future approaches to RP treatment (Musarella and Mac-
Donald, 2011). Today, gene therapy for RP has been
successfully used in animal models (Chadderton et al., 2009;
Millington-Ward et al., 2011; Palfi et al., 2010; Pang et al., 2011;
Pinilla et al., 2007, 2009) and humans (Bainbridge et al., 2008;
Maguire et al., 2008, 2009). However, therapy for P23H
rhodopsin-induced RP represents a challenge because of its
autosomal dominant nature (Farrar et al., 2010). Molecules
that promote survival, such as brain-derived neurotrophic
factor, ciliary neurotrophic factor, fibroblast growth factor,
glial-derived neurotrophic factor, and pigment epithelium-
derived factor, are moderately successful in preventing dis-
ease progression when used in animal models (Cayouette
et al., 1998, 1999; Chong et al., 1999; Green et al., 2001; McGee
Sanftner et al., 2001; Okoye et al., 2003). Antioxidants also
provide modest retinal protection in animal models of RP,
probably by reducing oxidative damage (Ahuja et al., 2005;
Berson et al., 1993; Komeima et al., 2006; Lax et al., 2011).
Finally, attenuation of apoptosis represents a good therapeutic
target in RP, especially considering the vast heterogeneity of
the disease (Doonan and Cotter, 2004; Lax et al., 2011; Liang
et al., 2001). In that sense, tauroursodeoxycholic acid, a com-
ponent of bear bile, has been shown to exhibit antiapoptotic
properties in neurodegenerative diseases and the capacity to
preserve cone and rod structure and function together with
their contacts with postsynaptic neurons (Boatright et al., 2006,
2009; Fernandez-Sanchez et al., 2011; Phillips et al., 2008).
Proinsulin, a member of the insulin superfamily, has been
characterized as a neuroprotective molecule that is active in
development and aging (de la Rosa and de Pablo, 2011; de
Pablo and de la Rosa, 1995; Vergara et al., 2012). During
embryonic retinal development, proinsulin acts as a survival
factor in chick and mouse (Diaz et al., 2000; Duenker et al.,
2005; Hernandez-Sanchez et al., 1995; Valenciano et al., 2006).
Conversely, treatment with exogenous proinsulin in ovo
results in a reduction of naturally occurring apoptosis
(Hernandez-Sanchez et al., 2003), and experimentally in-
duced cell death in the developing retina is prevented by
proinsulin (Diaz et al., 2000). In the rod-specific insulin
receptor (InsR) knockout mouse, increased sensitivity to
light-induced photoreceptor degeneration was observed,
providing direct evidence of a functional role for the InsR in
photoreceptor cell survival (Rajala et al., 2008). Finally,
transgenic expression of human proinsulin in skeletal muscle
in the rd10 mouse model of RP attenuated retinal degener-
ation, as assessed by the maintenance of electroretinographic
(ERG) responses and the histological preservation of photo-
receptors (Corrochano et al., 2008). Systemic proinsulin was
able to reach retinal tissue, delay apoptotic death of photo-
receptors, and decrease oxidative damage. Thus, proinsulin
represents a potential new therapy for RP and a new tool to
characterize the mechanisms involved in pathologic cell
death. Here we assess the therapeutic potential of proinsulin
on photoreceptor degeneration, synaptic connectivity, and
functional activity of the retina in the transgenic P23H rat
using adeno-associated vector (AAV)-mediated expression.
Materials and Methods
Animals
Homozygous P23H (line 3) albino rats, obtained from
Dr. M. LaVail (UCSF School of Medicine; www.ucsfeye.net/
mlavailRDratmodels.shtml), were used in this study. All
animals were bred in a colony at the Universidad de Alicante
and maintained under controlled humidity (60%), tempera-
ture (23–1C), and photoperiod (light:dark 12:12) conditions.
All animals were handled in accordance with current regu-
lations for the use of laboratory animals (National Institutes
of Health, Association for Research in Vision and Ophthal-
mology, and the European Directive 86/609/EEC) in order
to minimize animal suffering and numbers used for experi-
ments.
AAV vector production and administration
Vectors were generated by triple transfection method in
human embryonic kidney 293 cells according to standard
protocols (Matsushita et al., 1998). Cells were cultured to 80%
confluence in roller bottles (Corning, New York, NY) in
Dulbecco’s modified Eagle’s medium 10% fetal bovine serum
and co-transfected using the calcium phosphate method.
Expression of the human proinsulin cDNAwas driven by the
cytomegalovirus promoter. AAV-null vectors are noncoding
vectors and were produced using pAAV-MCS plasmid
(Stratagene, La Jolla, CA). AAVs were purified with an op-
timized method based on a polyethylene glycol precipitation
step and two consecutive cesium chloride (CsCl) gradients
(Ayuso et al., 2010). Purified AAV vectors were dialyzed
against phosphate-buffered saline, filtered, and stored at
- 80C. Titers of viral genomes were determined by quanti-
tative PCR following the protocol described for the AAV2
Reference Standard Material (Lock et al., 2010).
An adeno-associated viral vector serotype 1 (AAV1) ex-
pressing human proinsulin (hPi + ) was injected intramus-
cularly at a dose of 1013 vector genomes/kg to P23H rats at
P20. The total dose of vectors was distributed in quadriceps,
gastrocnemius, and tibialis cranialis muscles of both hind
limbs. Control animals received the same doses of AAV1-
null vector (hPi - ).
ERG recordings
Scotopic and photopic ERGs were performed at P30, P60,
P90, and P120. Following overnight dark adaptation, animals
were prepared for bilateral ERG recording under dim red
light. Animals were anesthetized by intraperitoneal injection
of a ketamine (100mg/kg; Imalgene, Merial Laboratorios
S.A., Barcelona, Spain) plus xylazine (4mg/kg; Xilagesic 2%,
Laboratorios Calier, Barcelona, Spain) solution, and main-
tained on a heated pad at 38C. Pupils were dilated by top-
ical application of 1% tropicamide (Alcon Cusı´, Barcelona,
Spain). A drop of Viscotears 0.2% polyacrylic acid carbomer
(Novartis, Barcelona, Spain) was instilled on the cornea to
prevent dehydration and allow electrical contact with the
recording electrodes (DTL fiber electrodes with an X-Static
silver-coated nylon conductive yarn; Sauquoit Industries,
Scranton, PA). A 25-gauge platinum needle inserted under
the scalp between the two eyes served as the reference
electrode. A gold electrode was placed in the mouth and
served as ground. Anesthetized animals were placed on a
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Faraday cage and all experiments were performed in abso-
lute darkness. Scotopic flash-induced ERG responses were
recorded from both eyes in response to light stimuli pro-
duced by a Ganzfeld stimulator. Light stimuli were pre-
sented for 10msec at 11 different increasing intensities
(ranging from - 5.7 to 0 log cd$sec/m2). Three to 10 con-
secutive recordings were averaged for each light presenta-
tion. The interval between light flashes was 10 sec for dim
flashes and up to 20 sec for the highest intensity. Photopic
responses were obtained after light adaptation at 10 cd/m2
during 20min, and stimuli were the same as for scotopic
conditions. The ERG signals were amplified and band-pass
filtered (1 to 1000Hz, without notch filtering) using a
DAM50 data acquisition board (World Precision Instru-
ments, Aston, UK). Stimulus presentation and data acquisi-
tion (4 kHz) were performed using a PowerLab system
(ADInstruments, Oxfordshire, UK). Recordings were saved
on a computer and analyzed off-line. The amplitude of the
a-wave was measured from the baseline to the trough of the
a-wave, and the results were averaged. The amplitude of
the b-wave was measured from the trough of the a-wave to
the peak of the b-wave and averaged for different recordings.
For both scotopic and photopic intensity-response curves,
thresholds were defined as the minimal luminance required
to reach the criterion amplitude of 10 lV.
Detection of serum proinsulin and glycemia
Blood samples were taken at P20, P30, P60, P90, and P120
to determine proinsulin levels in serum and glycemia. To
obtain the serum, blood was collected in anticoagulant-free
tubes, kept at room temperature until clot formation (around
30min) and then centrifuged (2000 · g, 15min at 4C). Serum
was transferred to tubes that were flash-frozen and then
stored at - 20C until analysis. The levels of human proin-
sulin in serum were measured using the Human Total
Proinsulin enzyme-linked immunosorbent assay (ELISA) kit
(Merck Millipore, Darmstadt, Germany) following manu-
facturer’s instructions. Glycemia was measured in situ by the
Glucocart Gmeter kit (A. Menarini Diagnostics Ltd.,
Berkshire, UK).
Retinal histology
Retinal sections. Animals were sacrificed upon admin-
istration of a lethal dose of pentobarbital, and their eyes were
enucleated, fixed in 4% paraformaldehyde, and sequentially
cryoprotected in 15%, 20%, and 30% sucrose. After being
washed in 0.1 M phosphate buffer (PB) pH 7.4, the cornea,
lens, and vitreous body were removed, and the retinas
were processed for vertical sections. For this purpose, they
were embedded in OCT and frozen in liquid N2. Sixteen-
micrometer-thick sections were then obtained at - 25C,
mounted on Superfrost Plus slides (Menzel GmbH & Co
KG, Braunschweig, Germany), and air-dried. Before further
use, slides were thawed and washed three times in PB, and
then treatedwith blocking solution (10%normal donkey serum
in PB plus 0.5% Triton X-100) for 1 hr at room temperature.
Retinal immunohistochemistry. For objective compari-
son, retinas from hPi + and hPi - rats were fully processed in
parallel. Primary antibodies used in this work are summa-
rized in Table 1. Sections were subjected to single or double
immunostaining overnight at room temperature with com-
binations of antibodies for different molecular markers at the
dilutions indicated in Table 1, in PB containing 0.5% Triton
X-100. Subsequently, Alexa Fluor 488 (green)–conjugated
anti-rabbit IgG and/or Alexa Fluor 555 (red)–conjugated
anti-mouse IgG donkey secondary antibodies from Mole-
cular Probes (Eugene, OR) were applied at a 1:100 dilution
for 1 hr. The sections were finally washed in PB, mounted in
Citifluor (Citifluor Ltd., London, UK) and coverslips applied
for viewing under laser-scanning confocal microscopy on
a Leica TCS SP2 system (Leica Microsystems, Wetzlar,
Germany). Immunohistochemical controls were performed
by omission of either the primary or secondary antibodies.
Final images from control and experimental subjects were
processed in parallel using the Adobe Photoshop 10 software
(Adobe Systems Inc., San Jose´, CA).
Retinal layer thickness. Animals were examined for
measurements of the outer nuclear layer (ONL) thickness,
using the nuclear stain TO-PRO-3 iodide (Molecular Probes)
added at a 1:1000 dilution, in at least two sections from each
animal containing the optic nerve and both temporal and
nasal orae serratae. Counting of photoreceptor rows was
performed at distances of 0.5, 1.5, 2.5, and 3.5mm from the
optic nerve toward each ora serrata. Quantifications were
done in a blinded fashion by multiple experienced observers.
Statistical analyses
Statistical analyses were performed using SPSS 15.0 soft-
ware (IBM, Armonk, NY). A repeated measures factorial
analysis of variance (ANOVA) was performed to evaluate
the effects of treatment (hPi + vs. hPi - ) on ERG responses
throughout the experimental stages (P30, P60, P90, and
P120), as well as the interactions among them. When a 0.05
level of significance was found, post hoc pairwise compari-
sons using Bonferroni’s test were performed. Normal distri-
butions and homogeneity of variance were found for all the
analyzed categories. A paired Student’s t-test was used when
only two groups were compared. A regression analysis was
performed to establish the relationship between the maxi-
mum scotopic ERG b-wave amplitude and the mean number
of rows of photoreceptor cell bodies in the ONL. P values less
than 0.05 were considered statistically significant. Data were
plotted as the average – standard error of the mean (SEM).
Results
AAV-mediated proinsulin production in P23H rats
P23H rats were intramuscularly injected with AAV1-hPi
or AAV1-null at P20. Human proinsulin was detected in
Table 1. Primary Antibodies
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serum at all times tested after vector administration (Fig. 1).
Average proinsulin levels ranged from 1.3 – 0.1 nM (P30) to
1.4 – 0.2 nM (P120). No proinsulin production was detected
in hPi - rats serum (not shown). To rule out potential met-
abolic effects of hPi expression, blood glucose levels of hPi +
rats were compared with those of hPi - animals over the
experimental period. We observed that glycemia increased
over time, a phenotype that has already been described in
wild-type male Sprague-Dawley rats (Petterino and Argentino-
Storino, 2006). Nevertheless, no significant differences in
glycemia were observed between hPi + and hPi - animals
(Student’s t-test, p = 0.11) (Fig. 1). These results show that the
AAV1 vector lead to high levels of hPi in serum, which do
not affect serum glucose levels.
Proinsulin preserves retinal responsiveness
In order to evaluate the effect of proinsulin on the func-
tional activity of the P23H rat’s photoreceptors, scotopic and
photopic flash-induced ERG responses were recorded in
hPi + and hPi - animals. As shown in Figure 2, ERG re-
sponsiveness was less deteriorated in hPi + rats compared to
control animals. Under scotopic conditions, the mean am-
plitudes recorded for b-waves were higher in hPi + animals,
compared to values obtained in control animals, at P90 and
P120 (ANOVA, Bonferroni’s test, p < 0.005 for P90, p < 0.001
for P120). Thresholds in hPi + animals, compared with
control rats, were lower for scotopic b-waves (Student’s
t-test p< 0.05) at both P90 (- 4.8 log cd$sec/m2 vs. - 3.9 log
cd$sec/m2) and P120 (- 3.5 log cd$sec/m2 vs. - 2.6 log
cd$sec/m2). There were no significant differences in the
scotopic a-waves or the photopic ERG responses between
hPi + and hPi - rats (data not shown).
Proinsulin slows photoreceptor degeneration
To assess the protective action of proinsulin on photore-
ceptors, we determined in each retina the mean number of
photoreceptor rows present in the ONL at P120, using the
nuclear dye TO-PRO-3. Because retinal degeneration in control
P23H rats was not homogeneous throughout the retina, we
studied the effects of proinsulin in different retinal areas, from
temporal to nasal.We found that the thickness of the ONLwas
higher in hPi+ (n= 10) than in control animals (n= 5) (Fig. 3;
p< 0.001 in nasal area P< 0.05 in temporal and central
area; Student’s t-test). Proinsulin showed its best neuropro-
tective effect at the ONL level in the nasal area of the retina
(Fig. 3), where 4-month-old hPi+ rats showed approxima-
tely 70% more rows of photoreceptor cell bodies than hPi-
animals (1.49– 0.04 vs. 0.87– 0.05, respectively). The mean
number of rows of photoreceptor cell bodies found in hPi+ rats
positively correlated with the maximum scotopic ERG b-wave
amplitude recorded for each animal at P120 (f= y0+ a· x,
R= 0.59, p< 0.01; where y0=y-intercept and a= slope).
Proinsulin preserves loss of ON bipolar cells
All rod bipolar cells and a particular subtype of amacrine
cells were labeled with antibodies against protein kinase C
(PKC), a isoform. In the P120 retinas of hPi - rats, rod bipolar
cells showed a substantial loss of cell bodies (Figs. 4A, 5A).
The number of immunopositive cells appeared to decrease,
and their cell bodies were not aligned in the orderly fashion
found in wild-type rats (Cuenca et al., 2004). In hPi + ani-
mals, the loss of bipolar cell bodies was not as extensive (Fig.
4B, 5B). Counting of bipolar cells in retinal sections showed a
greater number of immunopositive cells in the retinas of
hPi + animals (n = 10) compared to controls (n = 5). The dif-
ferences were significant in the temporal side of the retina,
where the degeneration was faster (Fig. 4C).
Proinsulin preserves synaptic connectivity
in the outer plexiform layer
We next explored in detail whether the preservation of
photoreceptors was accompanied by a preservation of syn-
aptic connectivity in the outer plexiform layer (OPL). To this
end, we used antibodies against bassoon, a protein constit-
uent of synaptic ribbons present in both rod spherules and
cone pedicles in the OPL. Typical bassoon-immunoreactive
spots were observed, with the horseshoe morphology cor-
responding to rod spherules (Fig. 5C, 5D, arrows). Few
bassoon-immunopositive spots were found at the OPL level
in P120 hPi - rats (Fig. 5C), indicating a decreased number of
photoreceptor axon terminals. However, hPi + animals
showed more bassoon-immunoreactive puncta (Fig. 5D),
indicating that the presynaptic contact elements between
FIG. 1. Serum proinsulin and glucose measured 10, 40, 70,
and 100 days after vector administration. (A) Serum levels of
human proinsulin (hPi) measured at P30, P60, P90, and P120
in P23H rats injected with adeno-associated viral vector se-
rotype 1 (AAV1)-hPi at P20. Note that significant expression
of hPi from the viral vectors was found as early as 10 days
after injection. No hPi was detected in serum from control rats
(not shown). (B) Glycemia in hPi+ and hPi- rats measured at
P20, P30, P60, P90, and P120. Error bars indicate SEM.
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photoreceptors and bipolar or horizontal cells were—at least
partially—preserved.
Proinsulin prevents loss of ON bipolar cell dendrites
and their synaptic contacts with photoreceptors
In the rat retina, dendritic terminals of ON rod bipolar
cells establish connections with rod spherules through a
large dendritic arbor in the OPL, and their axons run into the
inner plexiform layer, each one ending in a bulbous axon
terminal in the S5 stratum. In the retinas of P120 hPi - rats,
rod bipolar cells showed a substantial retraction of their
dendrites (Fig. 5A). Dendritic branches were scarce, and
some cells were almost entirely devoid of dendrites. By
contrast, in hPi + animals, bipolar cell dendrites were pre-
served (Fig. 5B). Double immunostaining for bassoon and
PKC showed the relationship between rod photoreceptor
axon terminals and bipolar cell dendritic tips. In retinas
from hPi - rats labeled at P120 with antibodies against these
two markers, few bassoon-positive dots (Fig. 5E) could be
seen paired with PKC-labeled bipolar cell dendrites (green).
However, in hPi + rat retinas the number of bassoon-
immunoreactive spots associated with bipolar cell dendritic
tips was clearly higher (Fig. 5F).
Proinsulin prevents loss of horizontal cell dendrites
and their synaptic contacts with photoreceptors
Horizontal cell bodies are located in the outermost inner
nuclear layer of the retina and establish connections with
both rod and cone photoreceptors. The only horizontal cell
subtype described in the rat retina can be identified using
antibodies against calbindin. In wild-type rats, calbindin la-
beling revealed a punctate staining of dendritic arborization
protruding from horizontal cell bodies and connecting with
cone axon terminals, together with thin tangential axonal
elongations in the OPL ending in an extensive arborization
connecting with rods (Cuenca et al., 2004). In hPi - rats at
P120, a retraction and loss of horizontal cell dendritic tips
was found concomitantly with the decrease of TO-PRO-3–
stained photoreceptor rows (Fig. 6A). In hPi + rat retinas, by
contrast, a higher number of horizontal cell terminals could
be observed (Fig. 6B). Double labeling with antibodies
against bassoon and calbindin showed numerous pairings
between photoreceptor axons and horizontal cell terminals in
hPi + animals (Fig. 6E) compared with fewer contacts ob-
served in hPi - rats (Fig. 6F). These data indicate a preserv-
ing effect of proinsulin on synaptic contacts between
photoreceptors and horizontal cells.
FIG. 2. Electroretinographic
(ERG) responses in control
(hPi - ) and proinsulin ex-
pressing (hPi + ) P23H rats.
Representative scotopic ERG
traces in a hPi - and a hPi +
rat at (A) P30, (B) P60, (C)
P90, and (D) P120. Units on
the left of the panels indicate
input flash intensities in log
cd$sec/m2. (E–H) Scotopic
ERG intensity-response curves
of b-waves in hPi - (circle)
and hPi + (square) rats at
different ages. Average am-
plitudes of scotopic b-waves
recorded in hPi + rats (n= 11)
were significantly higher
than those observed in hPi -
(n = 5) at P90 and P120. Paired
comparisons for each light
stimulus showed differences
between hPi + and hPi - an-
imals at P120. *p< 0.05; AN-
OVA, Bonferroni’s test. Error
bars indicate SEM.
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FIG. 3. Number of photo-
receptor rows in the outer
nuclear layer (ONL) under
hPi expression. Represen-
tative vertical sections from
(A) hPi - and (B) hPi + rat
retinas at P120 stained with
TO-PRO-3 iodide. Animals
treated with AAV1-hPi dis-
play a higher number of
photoreceptor rows at the
ONL than the untreated ani-
mals. (C) Average number of
photoreceptor rows at differ-
ent distance from the optic
nerve, along the naso-temporal
axis. Note that preservation
of photoreceptors is more
significant in the nasal retina
than in the temporal retina.
*p < 0.05, **p < 0.01; Student’s
t test. Scale bar: 50 lm. Error
bars indicate SEM.
FIG. 4. Rod bipolar cells
preservation by hPi. Re-
presentative vertical sections
from (A) control and (B)
hPi + rat retinas at P120. (C)
Immunostaining for protein
kinase C (PKC) and quantifi-
cation shows that hPi + rats
display a statistically signifi-
cant higher number of bipo-
lar cells than control hPi - in
the temporal retina. *p < 0.05;
**p < 0.01; ***p< 0.001; Stu-
dent’s t test. Scale bar: 50lm.
Error bars indicate SEM.
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Discussion
The present study demonstrates that hPi expression at-
tenuates retinal degeneration and the loss of retinal function
in P23H rats. Previous studies have already demonstrated
the neuroprotective effect of proinsulin (de la Rosa and de
Pablo, 2011; de Pablo and de la Rosa, 1995; Vergara et al.,
2012), and a recent study showed that transgenic expression
of human proinsulin in skeletal muscle in rd10 mice atten-
uates retinal degeneration (Corrochano et al., 2008). In this
work we analyzed the effects of human proinsulin expres-
sion on a rat model of autosomal dominant RP character-
ized by a slow-pace retinal degeneration, the P23H rat
(Cuenca et al., 2004; Pinilla et al., 2005). This is the first time
that proinsulin therapy has been assayed in this animal
model. To express proinsulin in these rats, we used a gene-
therapy approach. AAV vectors are becoming the vector of
choice for such in vivo approaches due to their excellent
safety and efficacy profiles. Among several serotypes, the
AAV1 is very efficient in transducing the skeletal muscle.
High levels of proteins can be secreted into the bloodstream
after the injection of this AAV1 into the skeletal muscle (Mas
et al., 2006; Riviere et al., 2006). Preclinical studies have
shown that AAV vector–mediated gene transfer results in
long-term gene expression in small and large animal models
of disease (Mingozzi and High, 2011). Importantly, the Eu-
ropean Medicines Agency has recently granted a market
authorization for the first gene therapy product in Europe
consisting of an AAV1 vector for treating lipoprotein lipase
deficiency, which gives support for the potential translation
of our approach into the clinic.
In the present study, P23H rats injected intramuscularly
with AAV1-hPi vector showed high and consistent levels of
proinsulin in the bloodstream (about 1300 pM). The meta-
bolic effects of prolonged systemic exposure to human pro-
insulin has been extensively investigated in clinical trials,
using hPi as an intermediate-acting insulin analog for dia-
betes therapy (Galloway et al., 1992). Notably, the hypogly-
cemic potency of proinsulin was*5% to 50% that of insulin
(Galloway et al., 1969; Jones et al., 1976; Sonksen et al., 1973;
Stoll et al., 1971). The serum hPi concentrations, ranging from
1400 to 8000 pM, were equal to or up to 5-fold higher than
those achieved in our present study. Importantly, safety
studies were performed in patients treated for up to 4 yr with
FIG. 5. Synaptic connectiv-
ity in outer plexiform layer
(OPL) and rod bipolar cells in
hPi - and hPi + P23H rats.
Immunostaining for PKC
(green) and Bassoon (red)
shows that the preservation
of photoreceptors correlates
with a preservation of their
synaptic connections (arrow-
heads) with the bipolar cells in
retinas from hPi treated ani-
mals (B, D, F) as compared to
control rats (A, C, E). Ar-
rowheads indicate cone pho-
toreceptor contacts. Scale bar:
10lm.
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hPi. Compared to insulin, there was no significantly in-
creased risk of retinopathy, arthralgia–arthritis syndromes,
or pulmonary embolism (Galloway et al., 1992).
Transgenic P23H rats mimic the clinical findings reported
for human patients with P23H RP (Machida et al., 2000;
Pinilla et al., 2005). These animals develop a progressive rod
dysfunction, albeit initially exhibiting a normal cone func-
tion. The loss of photoreceptors is accompanied by degen-
erative changes in the inner retina (Cuenca et al., 2004),
including a substantial degeneration of retinal ganglion cells
(Garcia-Ayuso et al., 2010; Kolomiets et al., 2010). P23H line
3 rats retain vision for relatively long periods of their
lives, similarly to findings in P23H humans, who exhibit
significantly better visual acuity and greater ERG amplitudes
than patients harboring other RP mutations (Berson et al.,
1991; Machida et al., 2000). The slow retinal degeneration that
takes place in P23H line 3 rats makes this animal model closer
to the human condition than other P23H lines and genetic
mouse models, thus giving the present results additional clin-
ical relevance. In our experiments, proinsulin was detected
from P30 to P120, a stage at which P23H animals can be con-
sidered to have undergone extensive retinal degeneration
(www.ucsfeye.net/mlavailRDratmodels.shtml; Fernandez-
Sanchez et al., 2011; Lax et al., 2011).
Proinsulin expression in P23H rats ameliorated the loss of
photoreceptors in these animals. Preservation was in con-
cordance with the higher amplitudes of mixed scotopic ERG
responses found in hPi + animals compared with control
animals. These results agree with previous studies carried
out in the rd10 retinal degeneration mouse model (Corro-
chano et al., 2008), in which transgenic hPi/rd10 animals
displayed more photoreceptor rows than rd10 animals, and
ERG amplitude values of bdim, OP, amax, bmax, bphot, and
flicker responses were also higher. The greater degree of
preservation of photoreceptors and ERG responses ob-
served in hPi/rd10 mice than in the present studies may be
attributable to differences in the experimental model. hPi/
rd10 mice produces hPi even before birth, while AAV1-hPi–
injected P23H rats expressed hPi after P20, when a significant
degeneration of both the structure and the visual response
of the retina had already occurred (Cuenca et al., 2004;
Pinilla et al., 2005). Additionally, the circulating levels of
proinsulin in both studies are quite different; in the pres-
ent work we obtained 100-fold higher levels of circulating
FIG. 6. Horizontal cell syn-
aptic contacts. Immunostain-
ing for calbindin (green) and
bassoon (red) shows a higher
number of connections (ar-
rowheads) between photore-
ceptors and horizontal cells in
retinas from hPi + rats (B, D,
F) than from hPi - animals
(A, C, E). Scale bar: 10lm.
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proinsulin (about 1300 pM) compared with the transgenic
mice (about 15 pM). In light of these results, we believe that
the therapeutic window of proinsulin for RP is very large
(and the toxicity threshold is high [Galloway et al., 1992]),
since therapeutic effects have been observed at very low
doses in rd10 transgenic mouse. At present, while the
minimal therapeutic dose of AAV vectors warrants further
studies prior to clinical development, we have clearly
demonstrated the efficacy of the approach in this proof-of-
concept study.
In addition to the preventive effects of hPi on photore-
ceptor number and function, P23H hPi + rats demonstrated
improved connectivity between photoreceptors and their
postsynaptic neurons and horizontal and bipolar cells. Both
presynaptic and postsynaptic elements, as well as synaptic
contacts between photoreceptors and bipolar or horizontal
cells, were preserved in hPi + rats. Furthermore, the number
of rod bipolar cell bodies, as well as the density of their
dendritic terminals, was higher in hPi + than in control rats.
These results suggest that the proinsulin effect on retinal
morphology and function may not be cell specific and,
therefore, may extend not only to photoreceptors but also to
other cell types in the retina. On the other hand, preservation
of the photoreceptor population may affect the inner retina,
preventing the occurrence of secondary degenerative chan-
ges in their postsynaptic neurons and subsequent retinal
circuitry remodeling.
It has been proposed that neuroprotective effects of pro-
insulin are exerted, at least in part, through both reducing
apoptotic processes and preventing oxidative damage.
Blocking antibodies targeting proinsulin induces apoptosis
in the early chick retina (Diaz et al., 2000), and treatment with
exogenous proinsulin in ovo results in a reduction in natu-
rally occurring apoptosis (Hernandez-Sanchez et al., 2003). In
the embryonic retina, proinsulin seems to block develop-
mental cell death at various levels, including activation of the
prosurvival PI3K/Akt and ERK pathways, stimulation of
prosurvival chaperones, and interference with caspases and
cathepsins (Chavarria et al., 2007; de la Rosa et al., 1998;
Valenciano et al., 2006). Experiments with a rod-specific InsR
knockout mouse suggest that reduction of InsR activation
could lead to apoptosis mediated by caspase-3 activation
(Rajala et al., 2008). Finally, it has been shown that transgenic
hPi expression in rd10 mice is able to delay apoptotic death
of photoreceptors and to decrease lipid oxidation damage
(Corrochano et al., 2008).
In summary the data in this study demonstrate that pro-
insulin represents a potential new therapy for retinal diseases,
and a new tool to characterize the mechanisms involved in
pathologic cell death. The use of therapies such as proinsulin,
effective not only in preserving photoreceptors from loss but
also in slowing the degeneration of inner retinal layers, may
be especially interesting in combination with other therapies
based on the implantation of new photoreceptors and the use
of anti-inflammatory agents, among others.
Acknowledgments
This research was supported by grants from MICINN
(BFU2009-07793/BFI, RETICS RD07/0062/0012-0008, and
SAF2010-21879), TRACE (PET08-0282), CDTI, ENISA (Pro-
Retina Therapeutics SL) and FUNDALUCE.
Author Disclosure Statement
Laura Ferna´ndez-Sa´nchez: F, ProRetina Therapeutics SL.
Pedro Lax: F, ProRetina Therapeutics SL. C. Isiegas: I, Pro-
Retina Therapeutics SL; E, ProRetina Therapeutics SL. Eduard
Ayuso: F, ProRetina Therapeutics SL; I, ProRetina Ther-
apeutics SL. Jose´ M. Ruiz: E, ProRetina Therapeutics SL; I,
ProRetina Therapeutics SL Pedro de la Villa: F, ProRetina
Therapeutics SL; I, ProRetina Therapeutics SL; P, ProRetina
Therapeutics SL. Fatima Bosch: F, ProRetina Therapeutics SL;
I, ProRetina Therapeutics SL; P, ProRetina Therapeutics SL.
Enrique J. de la Rosa: F, ProRetina Therapeutics SL; I, Pro-
Retina Therapeutics SL; P, ProRetina Therapeutics SL. Nicola´s
Cuenca: F, ProRetina Therapeutics SL. F, Financial Support; I,
Personal Financial Interest; E, Employment; P, Patent.
References
Ahuja, P., Caffe, A.R., Ahuja, S., et al. (2005). Decreased gluta-
thione transferase levels in rd1/rd1 mouse retina: replenish-
ment protects photoreceptors in retinal explants. Neuroscience
131, 935–943.
Ayuso, E., Mingozzi, F., Montane, J., et al. (2010). High AAV
vector purity results in serotype- and tissue-independent en-
hancement of transduction efficiency. Gene Ther. 17, 503–510.
Bainbridge, J.W., Smith, A.J., Barker, S.S., et al. (2008). Effect of
gene therapy on visual function in Leber’s congenital amau-
rosis. N. Engl. J. Med. 358, 2231–2239.
Berson, E.L., Rosner, B., Sandberg, M.A., and Dryja, T.P. (1991).
Ocular findings in patients with autosomal dominant retinitis
pigmentosa and a rhodopsin gene defect (Pro-23-His). Arch.
Ophthalmol. 109, 92–101.
Berson, E.L., Rosner, B., Sandberg, M.A., et al. (1993). A ran-
domized trial of vitamin A and vitamin E supplementation for
retinitis pigmentosa. Arch. Ophthalmol. 111, 761–772.
Boatright, J.H., Moring, A.G., McElroy, C., et al. (2006). Tool from
ancient pharmacopoeia prevents vision loss. Mol. Vis. 12,
1706–1714.
Boatright, J.H., Nickerson, J.M., Moring, A.G., and Pardue, M.T.
(2009). Bile acids in treatment of ocular disease. J. Ocul. Biol.
Dis. Infor. 2, 149–159.
Cayouette, M., Behn, D., Sendtner, M., et al. (1998). Intraocular
gene transfer of ciliary neurotrophic factor prevents death and
increases responsiveness of rod photoreceptors in the retinal
degeneration slow mouse. J. Neurosci. 18, 9282–9293.
Cayouette, M., Smith, S.B., Becerra, S.P., and Gravel, C. (1999).
Pigment epithelium-derived factor delays the death of pho-
toreceptors in mouse models of inherited retinal degenera-
tions. Neurobiol. Dis. 6, 523–532.
Chadderton, N., Millington-Ward, S., Palfi, A., et al. (2009). Im-
proved retinal function in a mouse model of dominant retinitis
pigmentosa following AAV-delivered gene therapy. Mol.
Ther. 17, 593–599.
Chavarria, T., Valenciano, A.I., Mayordomo, R., et al. (2007).
Differential, age-dependent MEK-Erk and PI3K-Akt activation
by insulin acting as a survival factor during embryonic retinal
development. Dev. Neurobiol. 67, 1777–1788.
Chong, N.H., Alexander, R.A., Waters, L., et al. (1999). Repeated
injections of a ciliary neurotrophic factor analogue leading to
long-term photoreceptor survival in hereditary retinal de-
generation. Invest. Ophthalmol. Vis. Sci. 40, 1298–1305.
Corrochano, S., Barhoum, R., Boya, P., et al. (2008). Attenuation
of vision loss and delay in apoptosis of photoreceptors in-
duced by proinsulin in a mouse model of retinitis pigmentosa.
Invest. Ophthalmol. Vis. Sci. 49, 4188–4194.
1298 FERNA´NDEZ-SA´NCHEZ ET AL.
Cuenca, N., Pinilla, I., Sauve, Y., et al. (2004). Regressive and reactive
changes in the connectivity patterns of rod and cone pathways of
P23H transgenic rat retina. Neuroscience 127, 301–317.
de la Rosa, E.J., and de Pablo, F. (2011). Proinsulin: from hor-
monal precursor to neuroprotective factor. Front. Mol. Neu-
rosci. 4, 20.
de la Rosa, E.J., Vega-Nunez, E., Morales, A.V., et al. (1998).
Modulation of the chaperone heat shock cognate 70 by em-
bryonic (pro)insulin correlates with prevention of apoptosis.
Proc. Natl. Acad. Sci. U. S. A. 95, 9950–9955.
de Pablo, F., and de la Rosa, E.J. (1995). The developing CNS: a
scenario for the action of proinsulin, insulin and insulin-like
growth factors. Trends Neurosci. 18, 143–150.
Diaz, B., Serna, J., de Pablo, F., and de la Rosa, E.J. (2000). In vivo
regulation of cell death by embryonic (pro)insulin and the
insulin receptor during early retinal neurogenesis. Develop-
ment 127, 1641–1649.
Doonan, F., and Cotter, T.G. (2004). Apoptosis: a potential
therapeutic target for retinal degenerations. Curr. Neurovasc.
Res. 1, 41–53.
Dryja, T.P., McGee, T.L., Reichel, E., et al. (1990). A point mu-
tation of the rhodopsin gene in one form of retinitis pigmen-
tosa. Nature 343, 364–366.
Dryja, T.P., McEvoy, J.A., McGee, T.L., and Berson, E.L. (2000).
Novel rhodopsin mutations Gly114Val and Gln184Pro in
dominant retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci.
41, 3124–3127.
Duenker, N., Valenciano, A.I., Franke, A., et al. (2005). Balance
of pro-apoptotic transforming growth factor-beta and anti-
apoptotic insulin effects in the control of cell death in the
postnatal mouse retina. Eur. J. Neurosci. 22, 28–38.
Farrar, G.J., Palfi, A., and O’Reilly, M. (2010). Gene therapeutic
approaches for dominant retinopathies. Curr. Gene Ther. 10,
381–388.
Fernandez-Sanchez, L., Lax, P., Pinilla, I., et al. (2011). Taur-
oursodeoxycholic acid prevents retinal degeneration in trans-
genic P23H rats. Invest. Ophthalmol. Vis. Sci. 52, 4998–5008.
Galloway, J.A., Root, M.A., Chance, R.E., et al. (1969). In vivo
studies of the hypoglycemic activity of porcine proinsulin.
Diabetes 18, 1.
Galloway, J.A., Hooper, S.A., Spradlin, C.T., et al. (1992). Biosyn-
thetic human proinsulin. Review of chemistry, in vitro and in
vivo receptor binding, animal and human pharmacology
studies, and clinical trial experience. Diabetes Care 15, 666–692.
Garcia-Ayuso, D., Salinas-Navarro, M., Agudo, M., et al. (2010).
Retinal ganglion cell numbers and delayed retinal ganglion
cell death in the P23H rat retina. Exp. Eye Res. 91, 800–810.
Green, E.S., Rendahl, K.G., Zhou, S., et al. (2001). Two animal
models of retinal degeneration are rescued by recombinant
adeno-associated virus-mediated production of FGF-5 and
FGF-18. Mol. Ther. 3, 507–515.
Hernandez-Sanchez, C., Lopez-Carranza, A., Alarcon, C., et al.
(1995). Autocrine/paracrine role of insulin-related growth
factors in neurogenesis: local expression and effects on cell
proliferation and differentiation in retina. Proc. Natl. Acad.
Sci. U. S. A. 92, 9834–9838.
Hernandez-Sanchez, C., Mansilla, A., de la Rosa, E.J., et al.
(2003). Upstream AUGs in embryonic proinsulin mrna control
its low translation level. EMBO J. 22, 5582–5592.
Illing, M.E., Rajan, R.S., Bence, N.F., and Kopito, R.R. (2002). A
rhodopsin mutant linked to autosomal dominant retinitis
pigmentosa is prone to aggregate and interacts with the
ubiquitin proteasome system. J. Biol. Chem. 277, 34150–
34160.
Jones, B.W., Watt, C.B., Frederick, J.M., et al. (2003). Retinal re-
modeling triggered by photoreceptor degenerations. J. Comp.
Neurol. 464, 1–16.
Jones, R.H., Dron, D.I., Ellis, M.J., et al. (1976). Biological prop-
erties of chemically modified insulins. I. Biological activity of
proinsulin and insulin modified at A1-glycine and B29-lysine.
Diabetologia 12, 601–608.
Kaushal, S., and Khorana, H.G. (1994). Structure and function in
rhodopsin. 7. Point mutations associated with autosomal
dominant retinitis pigmentosa. Biochemistry 33, 6121–6128.
Kolomiets, B., Dubus, E., Simonutti, M., et al. (2010). Late his-
tological and functional changes in the P23H rat retina after
photoreceptor loss. Neurobiol. Dis. 38, 47–58.
Komeima, K., Rogers, B.S., Lu, L., and Campochiaro, P.A. (2006).
Antioxidants reduce cone cell death in a model of retinitis
pigmentosa. Proc. Natl. Acad. Sci. U. S. A. 103, 11300–11305.
Lax, P., Otalora, B.B., Esquiva, G., et al. (2011). Circadian dys-
function in P23H rhodopsin transgenic rats: effects of exoge-
nous melatonin. J. Pineal Res. 50, 183–191.
Liang, F.Q., Aleman, T.S., ZaixinYang, et al. (2001). Melatonin
delays photoreceptor degeneration in the rds/rds mouse.
Neuroreport 12, 1011–1014.
Lock, M., McGorray, S., Auricchio, A., et al. (2010). Character-
ization of a recombinant adeno-associated virus type 2 Re-
ference Standard Material. Hum. Gene Ther. 21, 1273–1285.
Machida, S., Kondo, M., Jamison, J.A., et al. (2000). P23H rho-
dopsin transgenic rat: correlation of retinal function with
histopathology. Invest. Ophthalmol. Vis. Sci. 41, 3200–3209.
Maguire, A.M., Simonelli, F., Pierce, E.A., et al. (2008). Safety and
efficacy of gene transfer for Leber’s congenital amaurosis. N.
Engl. J. Med. 358, 2240–2248.
Maguire, A.M., High, K.A., Auricchio, A., et al. (2009). Age-
dependent effects of RPE65 gene therapy for Leber’s congen-
ital amaurosis: a phase 1 dose-escalation trial. Lancet 374,
1597–1605.
Marc, R.E., Jones, B.W., Watt, C.B., and Strettoi, E. (2003). Neural
remodeling in retinal degeneration. Prog. Retin. Eye Res. 22,
607–655.
Mas, A., Montane, J., Anguela, X.M., et al. (2006). Reversal of
type 1 diabetes by engineering a glucose sensor in skeletal
muscle. Diabetes 55, 1546–1553.
Matsushita, T., Elliger, S., Elliger, C., et al. (1998). Adeno-
associated virus vectors can be efficiently produced without
helper virus. Gene Ther. 5, 938–945.
McGee Sanftner, L.H., Abel, H., Hauswirth, W.W., and Flannery,
J.G. (2001). Glial cell line derived neurotrophic factor delays
photoreceptor degeneration in a transgenic rat model of reti-
nitis pigmentosa. Mol. Ther. 4, 622–629.
Millington-Ward, S., Chadderton, N., O’Reilly, M., et al. (2011).
Suppression and replacement gene therapy for autosomal
dominant disease in a murine model of dominant retinitis
pigmentosa. Mol. Ther. 19, 642–649.
Mingozzi, F., and High, K.A. (2011). Therapeutic in vivo gene
transfer for genetic disease using AAV: progress and chal-
lenges. Nat. Rev. Genet. 12, 341–355.
Musarella, M.A., and MacDonald, I.M. (2011). Current concepts
in the treatment of retinitis pigmentosa. J. Ophthalmol. 2011,
753547.
Okoye, G., Zimmer, J., Sung, J., et al. (2003). Increased expression
of brain-derived neurotrophic factor preserves retinal function
and slows cell death from rhodopsin mutation or oxidative
damage. J. Neurosci. 23, 4164–4172.
Palfi, A., Millington-Ward, S., Chadderton, N., et al. (2010).
Adeno-associated virus-mediated rhodopsin replacement
PROINSULIN SLOWS RETINAL DEGENERATION IN P23H RATS 1299
provides therapeutic benefit in mice with a targeted disrup-
tion of the rhodopsin gene. Hum. Gene Ther. 21, 311–323.
Pang, J.J., Dai, X., Boye, S.E., et al. (2011). Long-term retinal
function and structure rescue using capsid mutant AAV8
vector in the rd10 mouse, a model of recessive retinitis pig-
mentosa. Mol. Ther. 19, 234–242.
Petterino, C., and Argentino-Storino, A. (2006). Clinical chem-
istry and haematology historical data in control Sprague-
Dawley rats from pre-clinical toxicity studies. Exp. Toxicol.
Pathol. 57, 213–219.
Phillips, M.J., Walker, T.A., Choi, H.Y., et al. (2008). Taur-
oursodeoxycholic acid preservation of photoreceptor structure
and function in the rd10 mouse through postnatal day 30.
Invest. Ophthalmol. Vis. Sci. 49, 2148–2155.
Pinilla, I., Lund, R.D., and Sauve, Y. (2005). Enhanced cone
dysfunction in rats homozygous for the P23H rhodopsin
mutation. Neurosci. Lett. 382, 16–21.
Pinilla, I., Cuenca, N., Sauve, Y., et al. (2007). Preservation of
outer retina and its synaptic connectivity following subretinal
injections of human Rpe cells in the Royal College of Surgeons
rat. Exp. Eye Res. 85, 381–392.
Pinilla, I., Cuenca, N., Martinez-Navarrete, G., et al. (2009). In-
traretinal processing following photoreceptor rescue by non-
retinal cells. Vision Res. 49, 2067–2077.
Puthussery, T., and Taylor, W.R. (2010). Functional changes in
inner retinal neurons in animal models of photoreceptor de-
generation. Adv. Exp. Med. Biol. 664, 525–532.
Rajala, A., Tanito, M., Le, Y.Z., et al. (2008). Loss of neuropro-
tective survival signal in mice lacking insulin receptor gene in
rod photoreceptor cells. J. Biol. Chem. 283, 19781–19792.
Reme,C.E.,Grimm,C.,Hafezi, F., et al. (1998).Apoptotic cell death in
retinal degenerations. Prog. Retin. Eye. Res. 17, 443–464.
Riviere, C., Danos, O., and Douar, A.M. (2006). Long-term ex-
pression and repeated administration of AAV type 1, 2 and 5
vectors in skeletal muscle of immunocompetent adult mice.
Gene Ther. 13, 1300–1308.
Sonksen, P.H., Tompkins, C.V., Srivastava, M.C., and Nabarro, J.D.
(1973). A comparative study on the metabolism of human insulin
and porcine proinsulin in man. Clin. Sci. Mol. Med. 45, 633–654.
Stoll, R.W., Touber, J.L., Winterscheid, L.C., et al. (1971). Hypogly-
cemic activity and immunological half-life of porcine insulin and
proinsulin in baboons and swine. Endocrinology 88, 714–717.
Valenciano, A.I., Corrochano, S., de Pablo, F., et al. (2006).
Proinsulin/insulin is synthesized locally and prevents cas-
pase- and cathepsin-mediated cell death in the embryonic
mouse retina. J. Neurochem. 99, 524–536.
Vergara, M.N., de la Rosa, E.J., and Canto-Soler, M.V. (2012).
Focus on molecules: proinsulin in the eye: precursor or pio-
neer? Exp. Eye Res. 101, 109–110.
Address correspondence to:
Dr. Nicola´s Cuenca
Departamento de Fisiologı´a, Gene´tica y Microbiologı´a
Universidad de Alicante





Received for publication March 28, 2012;
accepted after revision August 28, 2012.
Published online: September 27, 2012.
1300 FERNA´NDEZ-SA´NCHEZ ET AL.
